Tenofovir

替诺福韦

Report date: 2026/03/13 20:02:36

Base Information

Drug NameTenofovir
Drug Alias Name泰诺福韦(R)-PMPAPMPA-IVPMPAGS-1278 +[6] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionReverse transcriptase inhibitors
TargetsReverse transcriptase
Therapy Area/IndicationsBreast FeedingPainFever +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaZambiaUnited States +[29] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGilead Inc
China Registration ClassN/A

Develop Information

Active CompaniesGilead Sciences IncUniversity Of Cape TownJohns Hopkins University +[6] 
Inactive CompaniesBristol Myers Squibb SrlcompanyNational Institutes Of HealthEunice Kennedy Shriver National Institute Of Child Health And Human Development +[14] 
Active IndicationsPainFeverHepatitis B +[6] 
Inactive IndicationsBreast FeedingCarcinoma, HepatocellularHepatitis D, Chronic +[4] 

Other Information

ATC CodeJ05AF07
Related LinksDrugBankKEGG